title: Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease.
abstract: The unilaterally lesioned 6-hyroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) has proved to be invaluable in advancing our understanding of the mechanisms underlying parkinsonian symptoms, since it recapitulates the changes in basal ganglia circuitry and pharmacology observed in parkinsonian patients(1-4). However, the precise cellular and molecular changes occurring at cortico-striatal synapses of the output pathways within the striatum, which is the major input region of the basal ganglia remain elusive, and this is believed to be site where pathological abnormalities underlying parkinsonian symptoms arise(3,5).    In PD, understanding the mechanisms underlying changes in basal ganglia circuitry following degeneration of the nigro-striatal pathway has been greatly advanced by the development of bacterial artificial chromosome (BAC) mice over-expressing green fluorescent proteins driven by promoters specific for the two striatal output pathways (direct pathway: eGFP-D1; indirect pathway: eGFP-D2 and eGFP-A2a)(8), allowing them to be studied in isolation. For example, recent studies have suggested that there are pathological changes in synaptic plasticity in parkinsonian mice(9,10). However, these studies utilised juvenile mice and acute models of parkinsonism. It is unclear whether the changes described in adult rats with stable 6-OHDA lesions also occur in these models. Other groups have attempted to generate a stable unilaterally-lesioned 6-OHDA adult mouse model of PD by lesioning the medial forebrain bundle (MFB), unfortunately, the mortality rate in this study was extremely high, with only 14% surviving the surgery for 21 days or longer(11). More recent studies have generated intra-nigral lesions with both a low mortality rate >80% loss of dopaminergic neurons, however expression of L-DOPA induced dyskinesia(11,12,13,14) was variable in these studies. Another well established mouse model of PD is the MPTP-lesioned mouse(15). Whilst this model has proven useful in the assessment of potential neuroprotective agents(16), it is less suitable for understanding mechanisms underlying symptoms of PD, as this model often fails to induce motor deï¬cits, and shows a wide variability in the extent of lesion(17, 18).    Here we have developed a stable unilateral 6-OHDA-lesioned mouse model of PD by direct administration of 6-OHDA into the MFB, which consistently causes >95% loss of striatal dopamine (as measured by HPLC), as well as producing the behavioural imbalances observed in the well characterised unilateral 6-OHDA-lesioned rat model of PD. This newly developed mouse model of PD will prove a valuable tool in understanding the mechanisms underlying generation of parkinsonian symptoms.
authors.affiliation: Centre for Neurobiology of Stress, Dept Biological Sciences, University of Toronto at Scarborough.
authors.forename: Sherri L
authors.initials: SL
authors.lastname: Thiele
authors.forename: Ruth
authors.initials: R
authors.lastname: Warre
authors.forename: Joanne E
authors.initials: JE
authors.lastname: Nash
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000172:deficiency / Q000378:metabolism; D008474:Medial Forebrain Bundle / Q000187:drug effects; D051379:Mice; D008822:Mice, Transgenic; D016627:Oxidopamine / Q000008:administration & dosage*; D010300:Parkinson Disease; D051381:Rats
chemical_list: D016627:Oxidopamine; D004298:Dopamine